When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost of $162,500 annually.

The approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...

Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

“CareMed is grateful for the opportunity to become a specialty pharmacy provider for Vanrafia ™ ,” said Benito Fernandez. “We are proud to add Vanrafia ™ for the treatment of primary immunoglobulin A ...

NEW HYDE PARK, N.Y., April 07, 2025 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia ™ (atrasentan), for the reduction of ...